CurifyLabs Oy. Health technology company CurifyLabs automates local drug manufacturing in pharmacies and hospital pharmacies with its technology. The company’s solution addresses global challenges related to drug suitability and availability.
There is a growing need for more efficient drug customization and local manufacturing. Several trends are driving this demand: populations are aging, chronic diseases are increasing, and drug supply disruptions are becoming more common. At the same time, pharmacies and hospitals face increasing efficiency requirements.
Unlike many factory-produced medicines, locally prepared extemporaneous drugs can be tailored to meet patients’ specific needs. For example, children may not always have access to commercially available medications in sufficiently small doses. Medications can also be reformulated into more easily consumable forms, such as a liquid instead of a tablet. In some cases, allergenic excipients need to be removed from the formulation.
The market for locally produced, so-called extemporaneous drugs is experiencing strong growth. In 2023, it was valued at approximately €15 billion, and it is expected to grow to €30 billion by 2033.
The company’s investors include notable backers such as Lifeline Ventures, the Pharmacy Pension Fund (Apteekkien eläkekassa) and the Outpatient Care Research Foundation (Avohoidon tutkimussäätiö).
Investment in 2025.